Download pdf
Analysis of Financial Performances for Merck&Co: Comparison with Johnson&Johnson, Pfizer, and Bristol-Myers Squibb
- 1 Beijing World Youth Academy, Beijing, China
* Author to whom correspondence should be addressed.
Abstract
Medicines and medical resources are necessities of human society, and human beings often rely on them to speed up recovery or save lives. Especially since the society has just experienced an epidemic, namely COVID-19, the pharmaceutical industry is often in the spotlight. The prospects of the pharmaceutical industry are optimistic, and people often make profits by purchasing a company's stock. This study will analyze and evaluate the operating status of the four leader companies in the pharmaceutical market through data and theories, in order to figure out the most suitable company to buy shares. By comparing various data, Bristol-Myers Squibb's stock is the most suitable to buy. Because it has great potential in the future, high profitability, and high operation efficiency. The significance of this study is to enable people to discover companies worth investing in, provide professional advice to buyers, promote audiences for worthy companies, and discover companies with development prospects for the market.
Keywords
Financial analysis, pharmaceutical market, Merck&Co.
[1]. Richmond, L. and Stevenson, J. (2017) The pharmaceutical industry: a guide to historical records. Routledge.
[2]. Goodman, J. (2020) Pharmaceutical industry. In Medicine in the twentieth century (pp. 141-154). Taylor & Francis.
[3]. MRL Recruitment. (2023) Top 10 pharmaceutical companies in the US. Retrieved from: https://www.mrlcg.com/resources/blog/top-10-pharmaceutical-companies-in-the-us/.
[4]. Statista. (2023) Pharmaceuticals. Statista. Retrieved from: https://www.statista.com/outlook/hmo/pharmaceuticals/united-states#analyst-opinion.
[5]. Lazonick, W. and Tulum, Ö. (2024) Sick with “shareholder value”: US pharma’s financialized business model during the pandemic. Competition & Change, 28(2), 251-273.
[6]. Ilmiyono, A.F., Octavianty, E., Agustina, R.A. and Andriani, D.D. (2024) Effect of Macroeconomic and Profit Growth on the Stock Prices of Pharmaceutical Companies in Indonesia. The Accounting Journal of Binaniaga, 9(01), 65-74.
[7]. Charles, S. (2023). How to value company stocks: P/E, PEG, and P/B ratios. Retrieved from: https://www.schwab.com/learn/story/how-to-value-company-stocks-pe-peg-and-pb-ratios.
[8]. Bustos, O. and Pomares-Quimbaya, A. (2020) Stock market movement forecast: A systematic review. Expert Systems with Applications, 156, 113464..
[9]. Clemetson, J. (2023) Merck Closes Prometheus Acquisition: PHARMA: $10.8 B buyout'Largest Biotech Deal in San Diego'. San Diego Business Journal, 44(26), 2-4.
[10]. Howes, L. (2024) BMS closes 2023 with 2 big buys. C&EN Global Enterprise, 102(1), 8.
[11]. Bristol-Myers Squibb Company. (2024) Stock analysis: Bristol-Myers Squibb Company 10-K report. EDGAR, 14272, 44
Cite this article
Li,A. (2024). Analysis of Financial Performances for Merck&Co: Comparison with Johnson&Johnson, Pfizer, and Bristol-Myers Squibb. Advances in Economics, Management and Political Sciences,117,45-51.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 3rd International Conference on Financial Technology and Business Analysis
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).